Mallory Factor

New Capabilities

As of September 2026: Leading IntraBio through its second FDA approval

About 1 in 40,000 people are born with ataxia-telangiectasia, a genetic disease that destroys the cerebellum and progressively strips muscle control, typically starting in early childhood. Until this week, no drug was approved for it anywhere in the world. IntraBio's AQNEURSA (levacetylleucine) just became the first.

Updated Sep 21